Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS).

Fecha de publicación: 15/06/2023 Fecha Ahead of Print: 15/06/2023

Autores de IIS La Fe

Francisco Orbis Castellanos

Autor

Participantes ajenos a IIS La Fe

Alvarez Alvarez, Rosa
Manzano, Aranzazu
Agra Pujol, Carolina
Artigas Raventos, Vicente
Correa, Raquel
Cruz Jurado, Josefina
Fernandez, Juan Angel
Garcia del Muro, Xavier
Gonzalez, Jose Antonio
Hindi, Nadia
Lozano Lominchar, Pablo
Martinez-Trufero, Javier
Mendez, Ramiro
Munoz, Mercedes
Munoz Casares, Cristobal
Orellana Fernandez, Ruth
Paniagua Gonzalez, Miguel
Redondo, Andres
Valverde Morales, Claudia
Asencio, Jose Manuel

Grupos

Hepatología, Cirugia Hepatobiliopancreática y Trasplantes

Leader

Marina Berenguer Haym

Abstract

Soft tissue sarcomas (STS) are an uncommon and biologically heterogeneous group of tumors arising from mesenchymal cells. The incidence is estimated at five cases per 100,000 people per year. Retroperitoneal sarcomas (RPS) account for 10-15% of all STS, and their management depends on their anatomical characteristics and histotype. Due to their very low incidence, it is recommended that RPS be treated in reference centers and evaluated by an experienced multidisciplinary team (MDT). In Spain, the Spanish Group for Research in Sarcomas (GEIS) brings together experts from various specialties to promote research on sarcomas and improve treatment results. This paper summarizes the GEIS recommendations for the diagnosis, treatment, and follow-up of patients with RPS.